440 related articles for article (PubMed ID: 37232844)
1. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
2. Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose.
Christophorou E; Nilsson AC; Petersen I; Lindvig SO; Davidsen JR; Abazi R; Poulsen MK; Pedersen RM; Justesen US; Johansen NE; Bistrup C; Madsen LW; Johansen IS
Front Immunol; 2023; 14():1270814. PubMed ID: 38090591
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
4. Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Nelli F; Fabbri A; Botticelli A; Giannarelli D; Marrucci E; Fiore C; Virtuoso A; Berrios JRG; Scagnoli S; Pisegna S; Cirillo A; Panichi V; Massari A; Silvestri MA; Ruggeri EM
Front Oncol; 2023; 13():1280416. PubMed ID: 38023235
[TBL] [Abstract][Full Text] [Related]
5. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
7. Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Marrucci E; Fiore C; Giron Berrios JR; Schirripa M; Signorelli C; Chilelli MG; Primi F; Panichi V; Caterini L; Farinelli S; Silvestri MA; Ruggeri EM
Clin Exp Med; 2024 Jan; 24(1):13. PubMed ID: 38244147
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
Piñana JL; López-Corral L; Martino R; Vazquez L; Pérez A; Martin-Martin G; Gago B; Sanz-Linares G; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; Corona M; Marcos-Corrales S; Tormo M; Hernández-Rivas JÁ; Montoro J; Rodriguez-Fernandez A; Risco-Gálvez I; Rodríguez-Belenguer P; Hernandez-Boluda JC; García-Cadenas I; Ruiz-García M; Muñoz-Bellido JL; Solano C; Cedillo Á; Sureda A; Navarro D;
J Hematol Oncol; 2022 May; 15(1):54. PubMed ID: 35526045
[TBL] [Abstract][Full Text] [Related]
10. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
Martín Pérez C; Aguilar R; Jiménez A; Salmerón G; Canyelles M; Rubio R; Vidal M; Cuamba I; Barrios D; Díaz N; Santano R; Serra P; Santamaria P; Izquierdo L; Trilla A; Vilella A; Barroso S; Tortajada M; García-Basteiro AL; Moncunill G; Dobaño C
BMC Med; 2024 Mar; 22(1):103. PubMed ID: 38454385
[TBL] [Abstract][Full Text] [Related]
11. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
13. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
[TBL] [Abstract][Full Text] [Related]
14. Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
Tani N; Ikematsu H; Goto T; Kondo S; Gondo K; Fujiyoshi N; Minami J; Harada Y; Nagano S; Horiuchi T; Kuwano H; Akashi K; Shimono N; Chong Y
Vaccine; 2023 Oct; 41(45):6672-6678. PubMed ID: 37775465
[TBL] [Abstract][Full Text] [Related]
15. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
Seekircher L; Bánki Z; Kimpel J; Rössler A; Schäfer H; Falkensammer B; Bante D; Forer L; Schönherr S; ; Harthaller T; Sacher M; Ower C; Tschiderer L; Ulmer H; Krammer F; von Laer D; Borena W; Willeit P
Lancet Microbe; 2023 Aug; 4(8):e612-e621. PubMed ID: 37354911
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia.
Yang SL; Mat Ripen A; Leong CT; Lee JV; Yen CH; Chand AK; Koh K; Abdul Rahim NAB; Gokilavanan V; Mohamed NNEB; Sevalingam RKA; Sulaiman N; Ab Razak AKB; Mohd Nor NHB; Pong MK; Tai KY; Toh V; Woon YL; Peariasamy KM
Emerg Microbes Infect; 2022 Dec; 11(1):1262-1271. PubMed ID: 35412409
[TBL] [Abstract][Full Text] [Related]
17. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
18. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
19. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
